Advertisement

Annals of Nuclear Medicine

, Volume 5, Issue 2, pp 53–58 | Cite as

Metabolic reserve in normal myocardium assessed by positron emission tomography with C-11 palmitate

  • Nagara Tamaki
  • Masahide Kawamoto
  • Norio Takahashi
  • Yoshiharu Yonekura
  • Yasuhiro Magata
  • Ryuji Nohara
  • Hirofumi Kambara
  • Chuichi Kawai
  • Junji Konishi
Original Article

Abstract

Positron emission tomography (PET) with C-11 palmitate has been used in estimating the myocardial utilization of free fatty acid. To assess the metabolic reserve in normal subjects, a PET study was performed at control and during dobutamine infusion at 2 hour intervals in 5 normal subjects. Following monoexponential curve fitting of the time activity curve of the myocardium, the clearance half time (min) and residual fraction ( %) were calculated as indices of β-oxydation of free fatty acid. A significant increase in the heart rate and systolic blood pressure were observed during dobutamine infusion (65 ± 5 vs 100±29 bpm, p< 0.05 and 119±12 vs 144±16 mmHg, p< 0.01, respectively). The clearance half time and the residual fraction were significantly decreased (23.4±2.6 vs 15.8±2.3 min and 67.0±2.5vs 58.6± 4.0%, p< 0.05, each). When the left ventricular myocardium was divided into 4 segments, these indices were similar at control and uniformly decreased without regional differences during dobutamine infusion. These data suggest that β-oxydation of free fatty acid may be uniformly increased in the left ventricular myocardium in relation to the increase in cardiac work in normal subjects. PET with C-11 palmitate at control and during dobutamine infusion is considered to be promising in assessing metabolic reserve in the myocardium.

Key words

emission computed tomography C-11 palmitate fatty acid metabolism dobutamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weiss ES, Hoffman EJ, Phelps ME, et al: External detection and visualization of myocardial ischemia with C-11 substratesin vivo andin vivo.Circ Res 39: 24–32, 1976PubMedGoogle Scholar
  2. 2.
    Sobel BE, Weiss ES, Welch MJ, et al: Detection of remote myocardial infarction in patients with positron transaxial tomography and intravenous C-11 palmitate.Circulation 55: 853–857, 1977PubMedGoogle Scholar
  3. 3.
    Ter-Pogossian MM, Klein MS, Markham J, et al: Regional assessment of myocardial infarction in patients with positron emision tomography with C-11 palmitate.Circulation 61: 242–255, 1980PubMedGoogle Scholar
  4. 4.
    Bergmann SR, Lerch RA, Fox KAA et al: Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography.Am J Med 73: 753–581, 1982CrossRefGoogle Scholar
  5. 5.
    Geltman EM, Biello D, Welch MJ, et al: Characterization of nontransmural myocardial infarction by positron emission tomography.Circulation 65: 747–755, 1982PubMedGoogle Scholar
  6. 6.
    Schon HR, Schelbert HR, Robinson G, et al: C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography. I. Kinetics of C-11 palmitic acid in normal myocardium.Am Heart J 103: 532–547, 1982PubMedCrossRefGoogle Scholar
  7. 7.
    Schon HR, Schelbert HR, Nahaji A, et al: C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography. II. Kinetics of C-11 palmitic acid in acutely ischemic myocardium.Am Heart J 103: 548–561, 1982PubMedCrossRefGoogle Scholar
  8. 8.
    Schelbert HR, Henze E, Keen R, et al: C-11 palmitate for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography. IV.In vivo evaluation of acute demand-induced ischemia in dogs.Am Heart J 106: 736–750, 1983PubMedCrossRefGoogle Scholar
  9. 9.
    Schelbert H, Henze E, Sochor H, et al: Effects of substrate availability on myocardial C-11 palmitate kinetics by positron emission tomography in normal subjects and patients with ventricular dysfunction.Am Heart J 111: 1055–1064, 1986PubMedCrossRefGoogle Scholar
  10. 10.
    Grover-McKay M, Schelbert HR, Schwaiger M, et al: Identification of impaired metabolic reserve by atrial pacing in patients with significant coronary artery stenosis.Circulation 74: 281–292, 1986PubMedGoogle Scholar
  11. 11.
    Senda M, Tamaki N, Yonekura Y, et al: Performance characteristics of Positologica III, a whole body positron emission tomograph.J Comput Assist Tomogr 9: 940–946, 1985PubMedCrossRefGoogle Scholar
  12. 12.
    Yonekura Y, Tamaki N, Kambara H, et al: Detection of metabolic alterations in ischemic myocardium by F-18 fiuorodeoxyglucose uptake with positron emission tomography.J Am Cardiac Imag 2: 122–132, 1988Google Scholar
  13. 13.
    Stratmann HG, Kennedy H: Evaluation of coronary artery disease in the patients unable to exercise: alternatives to exercise stress testing.Am Heart J 117: 1344–1365, 1989PubMedCrossRefGoogle Scholar
  14. 14.
    Mannering D, Cripps T, Leech G, et al: The dobutamine stress test as an alterative to exercise testing after acute myocardial infarction.Br Heart J 59: 521–526, 1988PubMedCrossRefGoogle Scholar
  15. 15.
    Brown M, Marshall DR, Sobel BE, et al: Delineation of myocardial utilization with carbon-11-labeled acetate.Circulation 76: 687–696, 1987PubMedGoogle Scholar
  16. 16.
    Brown MA, Myears DW, Bergmann SR: Validity of estimates of myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography despite altered patterns of substrate utilization.J Nucl Med 30: 187–193, 1989PubMedGoogle Scholar
  17. 17.
    Buxton DB, Nienaber CA, Luxen A, et al: Non-invasive quantitation of regional myocardial oxygen consumptionin vivo with 1-11C acetate and dynamic positron emission tomography.Circulation 79: 134–142, 1989PubMedGoogle Scholar
  18. 18.
    Tamaki N, Yonekura Y, Magata Y, et al: Fatty acid metabolism using C-11 palmitate: I. Resting study.Kaku Igaku 27: 313–321, 1990 (in Japanese)PubMedGoogle Scholar
  19. 19.
    Tuttle RR, Millis J: Dobutamine. Development of new catecholamine to selectively increase cardiac contractility.Circ Res 36: 185–196, 1975PubMedGoogle Scholar
  20. 20.
    Meyer SL, Curry GC, Donsky MS, et al: Influence of dobutamine on hemodynamics and coronary blood flow in patients with and without coronary artery disease.Am J Cardiol 38: 103–108, 1976PubMedCrossRefGoogle Scholar
  21. 21.
    Mason JR, Palac RT, Freeman ML, et al: Thallium-201 scintigraphy during dobutamine infusion: non-exercise-dependent screening test for coronary disease.Am Heart J 107: 481–485, 1984PubMedCrossRefGoogle Scholar
  22. 22.
    Berthe C, Pierard LA, Hiernaux M, et al: Predicting the extent and location of coronary artery disease in acute myocardial infarction by echocardiography during dubutamine infusion.Am J Cardiol 58: 1167–1172, 1986PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Nagara Tamaki
    • 1
  • Masahide Kawamoto
    • 1
  • Norio Takahashi
    • 1
  • Yoshiharu Yonekura
    • 1
  • Yasuhiro Magata
    • 1
  • Ryuji Nohara
    • 2
  • Hirofumi Kambara
    • 2
  • Chuichi Kawai
    • 2
  • Junji Konishi
    • 2
  1. 1.Department of Nuclear MedicineKyoto University Faculty of MedicineKyotoJapan
  2. 2.Third Division, Department of Internal MedicineKyoto University Faculty of MedicineJapan

Personalised recommendations